NRIX vs VECO Comparison

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Veeco Instruments Inc is a United States-based company that is principally engaged in designing, developing, and manufacturing thin-film process equipment, which is mainly used to produce electronic devices. The company's product categories by market consist of lighting, display, and power electronics; advanced packaging; MEMS and RF; scientific and industrial; and data storage. The lighting, display, and power electronics market accounts for over half of the total revenue. The company offers products and services in the United States; China; Europe, the Middle East, and Africa, or EMEA; and the rest of the world, with overseas markets contributing the majority of total revenue.